AAPL

TSLA

AMZN

META

AMD

NVDA

PEP

COST

ADBE

GOOG

AMGN

HON

INTC

INTU

NFLX

ADP

SBUX

MRNA

Markets

CORT

Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week

March 27, 2026 — 07:52 pm EDT

Written by

Eric Volkman for

The Motley Fool->

Key Points

- It earned FDA approval for its cancer drug, Lifyorli.

- This earned a recommendation upgrade from an analyst.

- 10 stocks we like better than Corcept Therapeutics ›

One of the top-performing healthcare stocks mid-week was Corcept Therapeutics (NASDAQ: CORT), and it was little wonder -- the company was granted U.S. Food and Drug Administration (FDA) approval for its leading drug candidate.

The double-digit pop Corcept experienced wasn't sustainable, as some investors booked quick profits after learning of the nod. Still, the stock landed in positive territory, posting a gain of just under 9% over the course of the week, according to data compiled by S&P Global Market Intelligence.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

A bright green light

The happy news was announced by Corcept on Wednesday. The product now ready for commercialization in this country is Lifyorli, which has been approved by the American healthcare regulator for use in combination with nab-paclitaxel (a chemotherapy drug) to treat the platinum-resitant stages of fallopian tube, primary peritoneal, and ovarian cancer.

Image source: Getty Images.

Patients who were previously administered one to three systemic treatment regimes are covered under the FDA's Lifyorli approval.

Later on Wednesday, Wolfe Research analyst Kalpit Patel upgraded his recommendation on Corcept stock, from underperform (sell, in other words) to peerperform (hold).

According to reports, Patel's change was -- unsurprisingly -- based on the FDA's Lifyorli nod. However, he continues to believe that the biotech's Korlym, a drug used to treat the hormonal disorder Cushing's syndrome, is weighing on its growth potential.

Selling into a high-demand market

To a degree, Patel has a point. Yet Corcept's success with Lifyorli not only gives it a marketable drug in a high-demand segment -- cancer -- but it also shows that the company's unique approach to development can work (it focuses on cortisol, the hormone at the heart of Cushing's syndrome). I'd be more bullish than the analyst on Corcept's future.

Should you buy stock in Corcept Therapeutics right now?

Before you buy stock in Corcept Therapeutics, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Corcept Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $503,268!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,049,793!*

Now, it’s worth noting Stock Advisor’s total average return is 898% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of March 27, 2026.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Corcept Therapeutics. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.